GlassScriptPhysician profile
Zachary John Hansen
NPI 1033787486
$1,914.71
in general payments reported to CMS, 2019-2025
27 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $16.14 · 2024: $351 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,914.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $289.30 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $151.40 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $149.32 | 2024-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $126.36 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $120.27 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Axsome Therapeutics, INC. | $108.97 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.96 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $96.15 | 2024-2025 | Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.89 | 2025 | Caplyta |
| Novo Nordisk INC | $86.84 | 2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $82.09 | 2025 | Veozah |
| Dexcom, INC. | $64.49 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $62.25 | 2024-2025 | |
| Corium, LLC | $52.84 | 2024-2025 | Azstarys |
| Pfizer INC. | $47.93 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $40.83 | 2025 | |
| Exact Sciences Corporation | $36.60 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $29.49 | 2025 | Zoryve |
| Inspire Medical Systems, INC. | $25.11 | 2025 | Inspire |
| Neuronetics, INC. | $23.27 | 2025 | Neurostar Tms Therapy System |
| Janssen Pharmaceuticals, INC | $22.08 | 2024 | Xarelto |
| Viatris Specialty LLC | $21.75 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $20.84 | 2025 | Enflonsia, Capvaxive, Gardasil 9 |
| Grifols USA, LLC | $16.85 | 2024 | Prolastin-C Liquid |
| Insulet Corporation | $16.14 | 2023 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.45 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $15.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.